RIPK3

Across TCGA pan-cancer cohorts, RIPK3 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of RIPK3’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where RIPK3 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types RIPK3 is over-expressed in tumor, although a few such as HNSC and LSCC show the opposite, repressed pattern.

HNSC, LSCC, and PDAC are the cancer types where RIPK3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RIPK3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	IV	−0.392	.002	9	view →
LSCC	Male	III,IV	−0.425	<.001	8	view →
PDAC	All	II,III,IV	+0.273	<.001	8	view →
CCRCC	All	All	+0.337	<.001	7	view →
COAD	All	II,III,IV	−0.135	<.001	7	view →
LUAD	Female	All	+0.170	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

RIPK3–HNSC

Open the HNSC breakdown →